Idera Pharmaceuticals (NASDAQ:[[ticker:IDRA]]), a Cambridge, MA-based developer of drugs that target a family of immune system receptors, reports it has inked a one-year extension to its research collaboration with New Jersey-based drug giant Merck. The two companies began the collaboration in December 2006 to investigate Idera’s drugs as treatments for cancer, infectious diseases, and Alzheimer’s.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
